Usually when you hear “little-known Canadian stock” you think, “hey, that’s probably some miner lying about their assay samples out of a storefront office in Vancouver” … but this one’s a little different. To start with, it’s not a mining stock, and has nothing to do with gold or tar sands or pipelines or any […]
Articles
- Most Relevant
- Most Recent
Ian Wyatt is selling his High-Yield Wealth newsletter by promising to help you get your first “gas rebate check” that can offset your high fuel expenses. Which sounds appealing, right? No one likes to fill up at the gas station, and people go gaga even for simple store card rebate programs that give you five […]
This ad caught my eye as readers were forwarding it in because it looks like a biotech pitch at first, but quickly morphs into a technology story. The spiel is all about stopping deaths, and about how it’s about time someone put a stop to the unnecessary level of pain and suffering we’re all suffering… […]
Today I thought we’d take a look at an Elliott Gue teaser for a stock that he thinks will be taken over by, of all people, the Rockefellers. Or maybe it’s The Rockefellers. He’s selling his Energy Strategist newsletter … and you’ll see why this teaser specifically appealed to me in a minute. Here’s a […]
Marc Lichtenfeld, who we’ve covered a number of times in this space, focuses largely on biotech investments — he’s teased a number of them for a variety of different newsletters that he has helmed or contributed to, but it looks like he’s now launching a new letter from the Oxford Club called FirstLine Investor Alert. […]
Let’s start with a little exercise… this is the pivotal sentiment of the latest pitch from Chris Wood in his ad for Casey’s Extraordinary Technology newsletter: “The Stock Story I’m About To Share With You Is The BIGGEST Of My Entire Career” How often, do you imagine, is something similar said in an ad for […]
“To secure your chance at wealth you’ve only dreamed of, you must act BEFORE the NEXT shocking event, scheduled for Wednesday, September 23. “That’s when the rest of the world will learn what you’ll know just seconds from now… “We’re in the final warm-up laps now — the CEO’s news release I’ll tell you all […]
Nick Hodge has been focusing a lot on biotech-ish companies for his Early Advantage newsletter lately, and they usually end up being pretty early-stage stocks with good stories about some kind of breakthrough or unique compound or device and no real financials yet (meaning, little to no revenue or earnings) — just the kind of […]
A Few Things to Keep an Eye On[ed note: Michael Jorrin, aka “Doc Gumshoe,” is a medical writer (not a doctor) who shares his thoughts with us once or twice a month. As with all our guest authors, his words and opinions are his own] The stream – or should I say “torrent” – of medical and health-care related news doesn’t seem […]
Today we’ve got an interesting tease that a few readers sent in — it’s from the White Cap Report folks, who generally look for potentially high-octane growth stocks, and it’s about some kind of biotech stock. Here’s how they get our blood flowing this fine morning: “California Biotech Cleared to Bypass FDA – Next Month […]
Today we’ve got a teaser pitch from Marc Lichtenfeld to consider. It’s an ad for his Oxford Income Letter, but the “fountain of youth” pitch makes it sound like a wild ride of a biotech idea… so let’s dig in and see what we can find, shall we? Sometimes it’s best to start with the […]
The other four stocks teased by Jimmy Mengel for his Crow’s Nest newsletter aren’t necessarily as interesting (story wise) as the one we looked at yesterday… but I promised to try to ID them for you, so let’s jump right in. I should let you know, first, that some of these are guesses. As usual, […]
[Ed note: This article was originally published in June, 2013 when the shares of the stock teased, Alnylam (ALNY) were around $30 and the Oxford Club was saying that the first person to live to 1,000 is already alive … now they’re touting it as the holder of the “Magic” Keys to Immortality, but the […]
A confession: I just made a huge rookie mistake — I was finishing up a different article for you and kicked the computer’s plug out of the wall … plenty of cussing going on here at Gumshoe HQ today. And worse, I screwed up my backup system and wasn’t logged in right, so I lost […]
[ed note: This is the latest in a series of articles from medical writer “Doc Gumshoe” (who, yes, is not actually a doctor) — it’s on the hot topic if antibiotic resistance, and we’ll likely continue to see companies touted and teased that aim to either fight resistant bacteria or clean up hospitals to slow […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends. He does not typically focus on specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, […]
[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]
The good folks over at the Money Map Press are selling memberships in their “Passport Club” this week, and your impetus for signing up is that they will reveal their top-secret obesity drug that they think will be approved in about a week. The Passport Club, by the way, is one of those “lifetime” offers […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Remember that British group with frontman Robert Smith? […]
The pill pushed as the Pres pill.FORMULA FOCUS 1-855-457-0806.Another FOCUS is this the one Doc talked about?1-866-778-2646 Ext.1,if you want to order.You Gummarati lets get that thinkolator going full speed. Whisslepig the end
No, Balthasar is not a biotech company. Think fast! Aragorn, Legolas and Gimli. Athos, Porthos and Aramis. Jaclyn, Farrah and Kate. Kirk, Spock and Bones. Barry, Robin and Maurice. Shadrach, Meshach and Abednego. History and culture bestow trios upon us because threesomes keep us rapt. The Three Magi, liking the Gummune as they do, have […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends. He does not typically focus on specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, […]
There’s a clear winner in the “what readers are asking about” sweepstakes this morning, and it’s the latest pitch from Charles Mizrahi for his Park Avenue Investment Club (currently $99/yr) — so that ad must really be making the rounds, and we’ll fire up the Thinkolator to get you some answers today. The pitch is […]
Hey Travis, I received this in an email this morning and was wondering if you know the stock. Thanks! Craig Now, a promise like this would be preposterous coming from anyone else … however, when a person with Paul’s credentials comes forward, one is practically required to pay attention. After all, Paul’s $6 billion hedge […]
So… what’s going in in the Real Money Portfolio this week, as we close up shop and get ready for a bit of time with family and friends? I do have one buy to share with you today, I decided to pick up some shares of the stock that I wrote to you about a […]
Lots to talk about today… we’ll start with a quick teaser solution, then move on to some big picture thoughts, updates on the changes in my portfolio (a couple small buys), and some other little updates and cogitations. The teaser comes from Mike Cintolo’s Cabot Growth Investor, which is just what it sounds like: a […]
[Ed. Note: Dr. KSS writes about biotech and medicine for the Irregulars. He adheres to our trading restrictions, choses his own topics, and his words and opinions are his own. His past articles and most recent comments can be found at his Stock Gumshoe page.] Dr. Norchi called me at home this morning to provide […]
Ed note: this article was first published in 2015, but the ad continues to run and readers continue to ask about it, so we’re re-posting this teaser solution for you today. What follows has not been meaningfully updated or revised since it was originally published on March 14, 2015, though some minor updates have been […]
The last time Dr Al Sears crossed our path, his banner headline was that President Obama, “the most corrupt president in U. S. history,” issued a “Death Order” in 2016 that “could result in the needless deaths of 1.3 million American seniors this year.” That “Death Order” consisted in the appointment of Robert Califf, […]
Who is this for: Investors looking to make explosive profits with time horizons of multiple years What is this for: Exchange of ideas for how to position a portfolio for the next bullish cycle in uranium Why? After 30 hours of preliminary research, I have a strong feeling that we are on the cusp of […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends. He does not typically focus on specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, he […]
The conference is exclusively one on one meetings that each attendee has with each presenting company, so lots of face time and note taking. I will disperse my notes from this conference in the comment thread below.
Well, we finish out the week with yet another dramatic performance from the market-dominating tech stocks. Alphabet (GOOG) did better than expected and popped a bit, climbing further through the day, almost as much as the gains Microsoft (MSFT) made on a more dramatic ‘beat’ of expectations (though analysts have always been better at estimating […]
This ad has popped up several times over the course of the year, and it’s now running again with a slight variation — mostly to change the “urgent” trade date from April 15 to November 9… so I thought we should take a quick look. The basic idea is that Robert Williams has a team […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends. He does not typically focus on specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, he […]
Got some spam about these advertising a newsletter called ’The Near Future Report.’ A few details are revealed; you can find the pitch here: https://pros.bonnerandpartners.com/p/1706BNFLAUNCH/PBNFT702/Full For the first one, one of the mentions ’Project Titan.’ But that is an Apple initiative so I doubt that is the key clue. I also think we can rule […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for our Irregulars. He chooses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions. Visit his Stock Gumshoe page for more.] Bacteria are prokaryotes. Animal cells, fungi and plants are eukaryotes. Prokaryotes tend to be acellular and […]
The latest ad for The Casey Report caught my eye this week, partly because I thought they might be following in teasing eCobalt (ECSI)… but it turns out that’s not the case, this pitch from E.B. Tucker about the next cobalt bull market being driven by lithium-ion battery demand is all about two other cobalt […]
This is a pitch from Jason Stutman’s The Cutting Edge newsletter, his higher-end service from Angel Publishing (about $1,500/year), and what caught my eye was the headline promise that Harvard University is “calling for a 29,000% surge for one tiny company you’ve never heard of.” So what is it? Well, it’s appropriate that we’re looking […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends. He does not typically focus on specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, he […]